Key statistics
On Friday, Atossa Therapeutics Inc (YAG2:STU) closed at 7.01, 3.66% above its 52-week low of 6.77, set on Jan 30, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 7.40 |
|---|---|
| High | 7.61 |
| Low | 6.77 |
| Bid | 0.4685 |
| Offer | 0.482 |
| Previous close | 7.01 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 8.61m |
| Free float | 8.58m |
| P/E (TTM) | -- |
| Market cap | 41.51m USD |
| EPS (TTM) | -3.52 USD |
Data delayed at least 15 minutes, as of Jan 30 2026.
More ▼
Press releases
- Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook
- Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program
- Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025
- Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy
- Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer
- Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category
- Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium
- Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy
- Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen
- Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum
More ▼
